Eli Lilly and Company

November 25, 2015November 30, 2015

Eli Lilly Therapy for Metastatic Squamous NSCLC Gets FDA Approval

Lung Cancer, News

A novel treatment for a particularly deadly form of lung cancer has just been approved by the U.S. Food and Drug Administration (FDA) — Eli Lilly and Company‘s Portrazza (necitumumab) a monoclonal ... Read more

November 2, 2015November 2, 2015

Results in Fruquintinib Proof-of-Concept Phase II Clinical Trial for Non-Squamous NSCLC Show Promise

Lung Cancer, News

Pharmaceutical company Hutchison China MediTech Limited (Chi-Med) recently announced that its R&D drug subsidiary Hutchison MediPharma Limited (HMP) will receive a $10 million dollar milestone payment from its partner Eli Lilly and Company ... Read more

April 7, 2015April 7, 2015

Eli Lilly Releases Medicare Treatment and Cost Patterns Among Non-Small Cell Lung Cancer Patients

Lung Cancer, News

In a recent study entitled “Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer,” researchers summarize the current state of metastatic squamous ... Read more

December 16, 2014December 16, 2014

FDA Extends Cyramza Approval to Metastatic Non-small Cell Lung Cancer

Lung Cancer, News

The U.S. Food and Drug Administration (FDA) has expanded the use of Cyramza (ramucirumab) to include patients suffering from metastatic non-small cell lung cancer (NSCLC) — the most common type of lung cancer — ... Read more

June 2, 2014June 2, 2014

Study Reveals Eli Lilly Drug Extends Survival in Relapsed Lung Cancer

Lung Cancer, News

Eli Lilly investigators recently reported that they were able to prolong survival in patients with advanced, non small cell lung cancer who relapsed after initial treatment. The results of the drug ... Read more